DrugsJul 7, 2026

Ecnoglutide: First Official Approvals

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Jul 8, 2026

Abstract

In January 2026, ecnoglutide received its first approval in China for glycaemic control in adults with type 2 diabetes mellitus.

Ecnoglutide is a cAMP-biased GLP-1 receptor agonist being developed for type 2 diabetes and long-term weight management.
In March 2026, it was approved in China for long-term weight management in adults with obesity or overweight and weight-related comorbidities.
Ecnoglutide is undergoing clinical evaluation for adolescents with obesity and for adults with obesity alongside obstructive sleep apnoea and knee osteoarthritis.
An oral tablet formulation of ecnoglutide is currently in clinical development.

Simplified

Ecnoglutide is a cyclic adenosine monophosphate (cAMP)-biased glucagon-like peptide-1 (GLP-1) receptor agonist being developed by Sciwind Biosciences for the treatment of type 2 diabetes mellitus (T2DM) and for use in long-term weight management. In January 2026, subcutaneous ecnoglutide received its first approval, in China, for use in glycaemic control in adults with T2DM. Subsequently, in March 2026, ecnoglutide received approval in China for use (in combination with diet control and increased physical activity) in long-term weight management in adults with obesity or with overweight with one or more weight-related comorbidity. Ecnoglutide is also under clinical evaluation for use in adolescents with obesity, and in adults with obesity and obstructive sleep apnoea and adults with obesity and knee osteoarthritis. An oral tablet formulation of ecnoglutide is in clinical development. This article summarises the milestones in the development of ecnoglutide leading to these first approvals for T2DM and long-term weight management.

Full Text

Full text is available at the source.

View Full Text ↗

Funding

Competing interests

Declarations. Authorship and Conflict of interest: During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. Matt Shirley is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content. Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability: Not applicable.

PubMed

Ecnoglutide: First Official Approvals

Abstract

Full Text

Funding

Competing interests

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief